Title: Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response.
Journal: Blood 20170810
Title: Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.
Journal: Blood 20170810
Title: Isocitrate dehydrogenase mutations in myeloid malignancies.
Journal: Leukemia 20170201
Title: Exploring the Pathway: IDH Mutations and Metabolic Dysregulation in Cancer Cells: A Novel Therapeutic Target. MAY 29, 2015
Title: Alan H. Shih, et al. AG-221, a Small Molecule Mutant IDH2 Inhibitor, Remodels the Epigenetic State of IDH2-Mutant Cells and Induces Alterations in Self-Renewal/Differentiation in IDH2-Mutant AML Model in Vivo. Blood 2014 124:437.